Dyne Therapeutics joined PPMD for a community webinar on April 12, 2023 to discuss Dyne’s FORCE™ platform. Ashish Dugar, PhD, MBA, Dyne’s Chief Medical Affairs Officer, and Molly White, Dyne’s Vice President, Global Head of Patient Advocacy and KOL Engagement, discussed Dyne’s DELIVER clinical trial, a Phase 1/2 study evaluating DYNE-251 for the treatment of individuals with Duchenne muscular dystrophy who have mutations amenable to exon 51 skipping.